Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Diagnostic and Prognostic Role of FENDRR and CRNDE With DUSP1 and DMBT1 in Oral Leukoplakia and Oral Squamous Cell Carcinoma

NCT07906795 is registered in ClinicalTrials.gov with Amina Fouad Farag as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07906795 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Diagnostic and Prognostic Role of FENDRR and CRNDE With DUSP1 and DMBT1 in Oral Leukoplakia and Oral Squamous Cell Carcinoma
Lead sponsor
Amina Fouad Farag
Phase
Observational
Overall status
Completed
Start date
December 26, 2021
Completion date
August 29, 2025
Enrollment
62 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

oral leukoplakia (ol), oral squamous cell carcinoma (oscc)

Arms

As registered; 3 arms.

  • OSCC

    Oral squamous cell carinoma

  • OL

    Oral leukoplakia

  • Control

    Control

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Diagnostic potential of FENDRR, CRNDE, DUSP1 and DMBT1 From enrollment to August 29, 2023

    Expression of lncRNA-FENDRR and lncRNA-CRNDE (relative expression, 2\^-ΔΔCt, by real-time RT-PCR) and tissue levels of DUSP1 (pg/mg protein) and DMBT1 (ng/mg protein, by ELISA) are measured in each tissue specimen. Diagnostic accuracy is assessed with receiver operating characteristic (ROC) curve analysis: area under the curve (AUC) with 95% confidence interval, and sensitivity and specificity, for oral leukoplakia versus controls, oral squamous cell carcinoma versus controls, and oral squamous cell carcinoma versus oral leukoplakia. Accuracy is compared with PI3K, AKT, mTOR, ERK2 and MMP9 measured in the same specimens.

Lead sponsor's other trials

Amina Fouad Farag, most recent start first.

Similar trials

Same condition (Leukoplakia, Oral) and phase, most recent start first.